PL3967755T3 - Rozpuszczalna npp1 do zastosowania w sposobie leczenia kępek żółtych rzekomych (pseudoxanthoma elasticum) - Google Patents

Rozpuszczalna npp1 do zastosowania w sposobie leczenia kępek żółtych rzekomych (pseudoxanthoma elasticum)

Info

Publication number
PL3967755T3
PL3967755T3 PL21192925.2T PL21192925T PL3967755T3 PL 3967755 T3 PL3967755 T3 PL 3967755T3 PL 21192925 T PL21192925 T PL 21192925T PL 3967755 T3 PL3967755 T3 PL 3967755T3
Authority
PL
Poland
Prior art keywords
treatment
pseudoxanthoma elasticum
soluble npp1
npp1
soluble
Prior art date
Application number
PL21192925.2T
Other languages
English (en)
Inventor
Anthony Quinn
Nelson HSIA
Kim Lynette ASKEW
Gregory Grabowski
W. Charles O'neill
Tayeba KHAN
Zhiliang Cheng
Original Assignee
Inozyme Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inozyme Pharma, Inc. filed Critical Inozyme Pharma, Inc.
Publication of PL3967755T3 publication Critical patent/PL3967755T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21192925.2T 2014-12-19 2015-12-18 Rozpuszczalna npp1 do zastosowania w sposobie leczenia kępek żółtych rzekomych (pseudoxanthoma elasticum) PL3967755T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094943P 2014-12-19 2014-12-19
US201562249781P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
PL3967755T3 true PL3967755T3 (pl) 2024-08-19

Family

ID=56127864

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21192925.2T PL3967755T3 (pl) 2014-12-19 2015-12-18 Rozpuszczalna npp1 do zastosowania w sposobie leczenia kępek żółtych rzekomych (pseudoxanthoma elasticum)

Country Status (15)

Country Link
US (2) USRE49529E1 (pl)
EP (3) EP3967755B1 (pl)
JP (3) JP7685309B2 (pl)
KR (2) KR102833432B1 (pl)
CN (1) CN107109381A (pl)
AU (1) AU2015364411A1 (pl)
BR (1) BR112017012928A2 (pl)
CA (1) CA2971414A1 (pl)
CO (1) CO2017006032A2 (pl)
ES (2) ES2981606T3 (pl)
HK (1) HK1245662A1 (pl)
MX (3) MX2017007946A (pl)
PL (1) PL3967755T3 (pl)
RU (1) RU2770698C2 (pl)
WO (1) WO2016100803A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3377105A4 (en) 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
AU2019267545A1 (en) * 2018-05-08 2020-11-26 Yale University Compositions and methods for reducing progression of nephrolithiasis
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
CA3126839A1 (en) * 2019-01-18 2020-07-23 Inozyme Pharma, Inc. Treatment of diseases involving deficiency of enpp1 or enpp3
CN110669137B (zh) 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
WO2021252549A1 (en) * 2020-06-09 2021-12-16 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
MX2023005836A (es) * 2020-11-19 2023-08-17 Inozyme Pharma Inc Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
EP1032662B1 (en) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1259649B1 (en) 2000-02-23 2009-11-04 Pxe international Inc. Methods and composition for diagnosing and treating pseudoxanthoma elasticum and related conditions
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
RU2601154C2 (ru) 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3377105A4 (en) * 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH

Also Published As

Publication number Publication date
EP3234116B1 (en) 2021-09-08
KR102833432B1 (ko) 2025-07-14
JP7685309B2 (ja) 2025-05-29
BR112017012928A2 (en) 2018-05-15
EP4438118A2 (en) 2024-10-02
US10493135B2 (en) 2019-12-03
RU2770698C2 (ru) 2022-04-21
USRE49529E1 (en) 2023-05-16
ES2981606T3 (es) 2024-10-09
JP2018500315A (ja) 2018-01-11
MX2022011281A (es) 2022-10-18
MX2017007946A (es) 2017-09-15
AU2015364411A1 (en) 2017-06-08
RU2017119466A (ru) 2019-01-21
RU2017119466A3 (pl) 2019-12-20
US20180318400A1 (en) 2018-11-08
CN107109381A (zh) 2017-08-29
EP4438118A3 (en) 2024-12-04
KR20170095367A (ko) 2017-08-22
ES2899895T3 (es) 2022-03-15
CA2971414A1 (en) 2016-06-23
CO2017006032A2 (es) 2017-10-20
JP2022003048A (ja) 2022-01-11
HK1245662A1 (zh) 2018-08-31
JP2024010052A (ja) 2024-01-23
EP3234116A4 (en) 2018-08-01
WO2016100803A2 (en) 2016-06-23
EP3967755A1 (en) 2022-03-16
MX2023006083A (es) 2023-06-19
WO2016100803A3 (en) 2016-08-04
EP3234116A2 (en) 2017-10-25
EP3967755B1 (en) 2024-03-27
KR20250111233A (ko) 2025-07-22

Similar Documents

Publication Publication Date Title
NL301263I2 (nl) elacestrant, desgewenst in de vorm van elacestrantdihydrochloride
PL3967755T3 (pl) Rozpuszczalna npp1 do zastosowania w sposobie leczenia kępek żółtych rzekomych (pseudoxanthoma elasticum)
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
SI3215601T1 (sl) Postopki za transdukcijo in obdelavo celic
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
SI3394065T1 (sl) Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
HUE037250T2 (hu) Duokarmicin ADC-k (antitest-hatóanyag konjugátumok) húgyhólyagrák kezelésében történõ alkalmazásra
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
PL3117777T3 (pl) Metoda tomografii rozpraszającej i urządzenie do tomografii rozpraszającej
SI3192129T1 (sl) Označevalni trak in postopek zanj
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse
IL251904A0 (en) Apilimod for use in the treatment of melanoma
DE102014001423A8 (de) Belüftungsvorrichtung
DE112015003378A5 (de) Haltevorrichtung zum lösbaren Halten von Gegenständen
DK3166945T3 (da) Hidtil ukendte triazolopyrimidinon- eller triazolopyridinderivater og anvendelse deraf
IL251345A0 (en) Compositions for use in the treatment of peri-implantitis
GB201417771D0 (en) Measuring device and related methods
IL248792A0 (en) Hsp70 modulators and methods for making and using the same
DK3234927T3 (da) Taxameter til brug i køretøjer og metode for dette
IL258567A (en) Colloidal particles for use in medicine
PL3125964T3 (pl) Środki antykoncepcyjne i pokrewne
SG11201608473RA (en) Devices and kits for measuring biological results